Regulation
Ipsen - September 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers ) Market: Euronext Paris ISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 September 2026 83,814,526 Gross total* of voting rights: 132,065,045 Net
Virbac : Declaration of the number of shares et voting rights 09/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights September, 30 2026 8 390 660 Gross total of voting rights : 12 705 414 Ne
Transactions in connection with share buy-back program
Company announcement no. 38 - 26 06 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 - 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules. The purposes
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 5 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initi
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, wh
EC-Council Releases ADG 2.0 and Offers Its AI Governance Crosswalks Free to Every Government, Regulator and Standards Body as Nations Split on AI Rules
With autonomous no global treaty in sight, EC-Council will assist any public authority that asks to map ADG 2.0 s 180+ controls to its own laws and standards HYDERABAD, India, Oct. 1, 2026 -- EC-Council today released ADG 2.0, the second version of its Adopt, Defend, Govern framework, and offered the framework and its crosswalks to more than 90 regulations, standards and global frameworks at no cost to any government, regulator or standards body in the world. EC-Council will also assist any of those that reach out, helping officials apply ADG 2.0 to their own laws, draft rules and national standards, consistent with applicable law.
Orion Corporation: Acquisition of own shares during week 40, 2026
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 30/09/2026 at 09.00 EEST Orion Corporation: Acquisition of own shares during week 40, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission
Equillium Announces Poster Presentations at the 7th International AHR Conference
New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulation LA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference , taking place September 29 to October 2, 2026, in Porto, Por
Transactions in connection with share buy-back program
Company announcement no. 37 - 26 29 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 - 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules. The purpose
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme in
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,
Orion Corporation: Acquisition of own shares during week 39, 2026
Orion Corporation: Acquisition of own shares during week 39, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. Orion Corporation’s shares have been acquired as follows: Date
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received a positive decision from GMED regarding certification of its quality management system to ISO 13485. GMED is a notified body designated under the European Union Medical Device Regulation (MDR). The Company continues to work with GMED toward completion of the remaining applicable MDR conformity asses
Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent
FDA Clearance and CE Mark Complete Aptiva s Antiphospholipid Syndrome Portfolio, Expanding Global Access to Comprehensive APS Testing SAN DIEGO , Sept. 23, 2026 -- Werfen today announced that its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin A (IgA) Reagent has received both U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark under the European Union s In Vitro Diagnostic Medical Devices Regulation (IVDR). Together, these milestones complete the Aptiva APS testing portfolio, which now offers all three APS isotypes, IgA, IgG, and IgM, for both anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (a GP1) antibodies.
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com Date Number of Shares Outstanding Total number of voting rights Total voting rights, theoretical 1 Total voting rights,
Transactions in connection with share buy-back program
Company announcement no. 36 - 26 22 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 - 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules. The purpose
DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS FY 30 APRIL 2026
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain. DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 3
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 21 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme in
UN Global Compact Launches Sustainable Procurement Implementation Framework to Help Companies Turn Commitments into Action
NEW YORK , Sept. 21, 2026 -- The United Nations Global Compact today launched the Sustainable Procurement Implementation Framework, a practical global resource designed to help companies place sustainability at the core of procurement and translate sustainability commitments and requirements into day-to-day business practice. Launched during the High-Level Forum on Sustainable Procurement, held on the margins of the United Nations General Assembly, the Framework responds to a critical implementation challenge for companies operating across increasingly complex global value chains. While governments around the world are advancing regulations and policies to promote more responsible and sustainable supply chains, companies also need practical guidance to translate these expectations into the decisions, processes and supplier relationships managed by procurement functions every day.
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, September 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,
Comarch Named a Leader in the 2026 IDC MarketScape for Worldwide Compliant E-Invoicing Solutions
KRAK W, Poland , Sept. 21, 2026 -- Comarch has been named a Leader in the IDC MarketScape: Worldwide Compliant E-Invoicing Solutions 2026 Vendor Assessment (doc EUR154882626, September 2026). The report evaluates worldwide technology providers on both their current capabilities and their long term strategy for helping enterprises manage compliance across multiple jurisdictions. Our mission has always been to empower international businesses with a unified, global platform for e-invoicing. We believe this recognition by the IDC MarketScape proves we are delivering on that promise enabling our clients to navigate complex regulations effortlessly across 70+ markets, says Adam Beldzik, E-Invoicing Sector Director at Comarch.
Orion Corporation: Acquisition of own shares during week 38, 2026
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 18/09/2026 at 19.00 EEST Orion Corporation: Acquisition of own shares during week 38, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission
DXS INTERNATIONAL PLC (AQSE: DXSP): Timing of FY Results to 30 April 2026
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain. 18 September 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) Timing of FY Resu
Transactions in connection with share buy-back program
Company announcement no. 35 - 26 15 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 - 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules. The purpose
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 14 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme in
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,
Sanofi: Information concerning the total number of voting rights and shares - August 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société anonyme with a registered share capital of €2,415,546,786 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris Commercial and Companies Re
Orion Corporation: Acquisition of own shares during week 37, 2026
Orion Corporation: Acquisition of own shares during week 37, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. Orion Corporation’s shares have been acquired as follows: Date
Transactions in connection with share buy-back program
Company announcement no. 34 - 26 08 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 - 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules. The purpose
First licensed treatment now available for condition behind the UK’s leading cause of horse euthanasia
New veterinary treatment targets insulin dysregulation, the most common cause of laminitis in horses and ponies Bracknell, United Kingdom – Boehringer Ingelheim has announced the availability in Great Britain of the first licensed treatment for equine insulin dysregulation, the most common underlying cause of laminitis, which is the leading cause of euthanasia in horses in the UK. Laminitis is one of the most devastating conditions in equine health. The statistics surrounding the disease are sta
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme in
Virbac : Declaration of the number of shares and voting rights 08/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights August, 31 2026 8 390 660 Gross total of voting rights : 12 705 411 Net t
Virbac : Declaration of the number of shares and voting rights 07/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights July, 31 2026 8 390 660 Gross total of voting rights : 12 705 412 Net tot
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, September 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,
Orion Corporation: Acquisition of own shares during week 36, 2026
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 4 September 2026 at 19.00 EEST Orion Corporation: Acquisition of own shares during week 36, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Comm
Ipsen - August 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers ) Market: Euronext Paris ISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 August 2026 83,814,526 Gross total* of voting rights: 132,077,444 Net tot
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 08/31/2026 314,388,807 Total gross of voting rights: 314,388,807 Total net* of voting rights: 314,222,095 * Net total = total number of voting rights attached to shares – shares withou
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
Boehringer headquarters Ingelheim, Germany Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies 1 , targeting the key underlying driver of laminitis.² Studies showed that SCOVELLA® rapidly and significantly reduces hyperinsulinemia with effects showing within days of starting treatment. 4,6 Laminitis is one of the most significant causes of pain and disa
Transactions in connection with share buy-back program
Company announcement no. 33 - 26 01 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 - 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules. The purpose
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 31 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initi